Skip to main content

Advertisement

SpringerLink
Log in

The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently recommended as 2nd or 3rd line therapy for patients with chronic myeloid leukemia (CML) in first chronic phase or as salvage for patients with very advanced disease. As a consequence, numbers of HSCT in chronic phase have dropped significantly since the introduction of tyrosine kinase inhibitors (TKI), numbers of transplants in advanced disease to a lesser extent. These current recommendations consider primarily disease risk, defined as failure of TKI therapy; they might need to be adapted. We propose a more balanced appraisal of HSCT for individual patients which should include disease risk, transplant risk, and macroeconomic aspects. HSCT should be integrated into the treatment algorithms from diagnosis and be considered very early at first TKI failure for patients with high disease but low transplant risk. For patients with very advanced disease and high transplant risk in contrast, HSCT might only be recommended in a restricted research setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 357(3):258–265

    Article  CAS  PubMed  Google Scholar 

  2. Jabbour E, Kantarjian H (2014) Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89(5):547–556. doi:10.1002/ajh.23691

    Article  CAS  PubMed  Google Scholar 

  3. Hehlmann R (1998) A chance of cure for every patient with chronic myeloid leukemia? N Engl J Med 338(14):980–982. doi:10.1056/NEJM199804023381409

    Article  CAS  PubMed  Google Scholar 

  4. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, Investigators IRIS (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004

    Article  PubMed  Google Scholar 

  5. Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP, IRIS investigators (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758–3765. doi:10.1182/blood-2010-03-273979

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Jain N, O’Brien S (2013) The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment. Expert Rev Hematol 6(5):575–586. doi:10.1586/17474086.2013.835697

    Article  CAS  PubMed  Google Scholar 

  7. Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M, Rosti G (2014) First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 74(6):627–643

    Article  CAS  PubMed  Google Scholar 

  8. Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813–1826

    Article  CAS  PubMed  Google Scholar 

  9. Appelbaum FR (2007) Hematopoietic-cell transplantation at 50. N Engl J Med 357:1472–1475

    Article  CAS  PubMed  Google Scholar 

  10. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA (1984) Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1(8378):665–668

    Article  CAS  PubMed  Google Scholar 

  11. Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kröger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A (2013) European group for blood and marrow transplantation. Bone Marrow Transplant 48(9):1161–1167. doi:10.1038/bmt.2013.51

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Mackinnon S, Goldman JM (1987) Bone marrow transplantation for CML. Baillieres Clin Haematol 1(4):1055–1076

    Article  CAS  PubMed  Google Scholar 

  13. Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, Dreyling M (2013) ESMO guidelines working group. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Onco 24(Suppl 6):vi133–vi137. doi:10.1093/annonc/mdt297

    Google Scholar 

  14. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A (2014) European myeloma network. European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99(2):232–242. doi:10.3324/haematol.2013.099358

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101. doi:10.1056/NEJMoa1004383

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, Baldomero H, Chabannon C, Apperley J, Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation, and the European Leukemia Net (2014) Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Haematologica 99(5):908–915

    Article  PubMed Central  PubMed  Google Scholar 

  17. Fefer A, Einstein AB, Thomas ED, Buckner CD, Clift RA, Glucksberg H, Neiman PE, Storb R (1974) Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med 290(25):1389–1393

    Article  CAS  PubMed  Google Scholar 

  18. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J et al (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314(4):202–207

    Article  CAS  PubMed  Google Scholar 

  19. Gratwohl A, Schwendener A, Baldomero H et al (2010) Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica 95:637–643

    Article  PubMed Central  PubMed  Google Scholar 

  20. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 352(9134):1087–1092

    Article  CAS  PubMed  Google Scholar 

  21. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, Dini G, Rocha V, Passweg J, Sureda A, Tichelli A, Niederwieser D (2009) Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 115(20):4715–4726. doi:10.1002/cncr.24531

    Article  PubMed  Google Scholar 

  22. Gratwohl A (2012) The EBMT risk score. Bone Marrow Transplant 47(6):749–756

    Article  CAS  PubMed  Google Scholar 

  23. Gratwohl A, Goldman J, Gluckman E, Zwaan F (1985) Effect of splenectomy before bone-marrow transplantation on survival in chronic granulocytic leukaemia. Lancet 2(8467):1290–1291

    Article  CAS  PubMed  Google Scholar 

  24. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304(25):1529–1533

    Article  CAS  PubMed  Google Scholar 

  25. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12):2462–2465

    CAS  PubMed  Google Scholar 

  26. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from. HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolatemofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4):1620–1629

    Article  CAS  PubMed  Google Scholar 

  27. Gratwohl A, Baldomero H, Aljurf M et al (2010) Hematopoietic stem cell transplantation: a global perspective. JAMA 303(16):1617–1624

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz M, Kodera Y, Lipton J, Iida M, Pasquini MC, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D, Worldwide Network of Blood and Marrow Transplantation (WBMT) (2013) Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 98(8):1282–1290. doi:10.3324/haematol.2012.076349

    Article  PubMed Central  PubMed  Google Scholar 

  29. Pasquini MC (2012) Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology 17(Suppl 1):S79–S82

    PubMed  Google Scholar 

  30. López-Hernández MA, Alvarado-Ibarra M, González-Avante CM (2011) Overall survival of chronic myeloid leukemia patients treated with related donor hematopoieticstemcell transplant or imatinib. Rev Invest Clin 63(5):494–499

    PubMed  Google Scholar 

  31. Butturini A, Keating A, Goldman J, Gale RP (1990) Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 335(8700):1255–1258

    Article  CAS  PubMed  Google Scholar 

  32. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A (1994) Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European group for bone marrow transplantation. Chronic leukemia working party of the EBMT. Bone Marrow Transplant 14(3):407–410

    CAS  PubMed  Google Scholar 

  33. Autograft Trials Collaboration CML (2007) Autologous stem cell transplantation in chronic myeloid leukaemia: a meta-analysis of six randomized trials. Cancer Treat Rev 33(1):39–47

    Article  Google Scholar 

  34. Heim D, Gratwohl A (2008) Role of allogeneic transplantation in chronic myeloid leukemia. Expert Rev Hematol 1(1):41–50. doi:10.1586/17474086.1.1.41

    Article  PubMed  Google Scholar 

  35. Sorror ML (2010) Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hemato lEduc Program 2010:237–247

    Article  Google Scholar 

  36. Spellman S, Setterholm M, Maiers M, Noreen H, Oudshoorn M, Fernandez-Vina M, Petersdorf E, Bray R, Hartzman RJ, Ng J, Hurley CK (2008) Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplan 14:37–44

    Article  Google Scholar 

  37. Latham K, Little AM, Madrigal JA (2014) An overview of HLA typing for hematopoietic stem cell transplantation. Methods Mol Biol 1109:73–85

    Article  PubMed  Google Scholar 

  38. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, Shaw BE (2014) Unrelated adult stem cell donor medical suitability: recommendations from the world marrow donor association clinical working group committee. Bone Marrow Transplant. doi:10.1038/bmt.2014.67

    Google Scholar 

  39. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M (2013) CMV reactivation after allogeneic. HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7):1316–1324

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Bar M, Radich J (2013) Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia. J Natl Compr Canc Netw 11(3):308–315

    CAS  PubMed  Google Scholar 

  41. Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N (2013) Outcome of allogeneic. SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 92(4):487–496

    Article  CAS  PubMed  Google Scholar 

  42. Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D (2012) Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 119(17):4083–4090

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim D, Uhm J, Lambie A, Ellis L, Lipton JH (2014) A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 14:87–92

    Article  PubMed  Google Scholar 

  44. Lee SJ, Kukreja M, Wang T, Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT (2008) Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112(8):3500–3507

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880–1885. doi:10.1182/blood-2009-08-237115

    Article  CAS  PubMed  Google Scholar 

  46. Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M (2014) Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 4, CD010189. doi:10.1002/14651858.CD010189.pub2

    PubMed  Google Scholar 

  47. Eapen M, Logan BR, Appelbaum FR et al (2014) Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2014.09.006

    PubMed Central  Google Scholar 

  48. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ (2012) Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 47(6):810–816

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84(12):4064–4077

    CAS  PubMed  Google Scholar 

  50. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Loffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109(11):4686–4692. doi:10.1182/blood-2006-11-055186

    Article  CAS  PubMed  Google Scholar 

  51. Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, Hehlmann R; for the SchweizerischeArbeitsgemeinschaftfürKlinischeForschung (SAKK) and the German CML Study Group (2014) Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia J Cancer Res Clin Oncol Apr 10

  52. Jiang Q, Xu LP, Liu DH, Liu KY, Gale RP, Zhang MJ, Jiang B, Zhang XH, Wang Y, Chen SS, Zhao XY, Chen H, Jiang H, Chen YH, Han W, Qin YZ, Liu YR, Lai YY, Lv M, Huang XJ (2013) Imatinib results in better outcomes than. HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 27(12):2410–2413. doi:10.1038/leu.2013.159

    Article  CAS  PubMed  Google Scholar 

  53. Liu YC, Hsiao HH, Chang CS, Liu TC, Yang WC, Hsu JF, Huang CT, Cho SF, Wu CH, Tsai YF, Lin SF (2013) Outcome of allotransplants in patients with chronic-phase chronic myeloid leukemia following imatinib failure: prognosis revisited. Anticancer Res 33(10):4663–4667

    CAS  PubMed  Google Scholar 

  54. Hamidieh AA, Ansari S, Darbandi B, Soroush A, Arjmandi Rafsanjani K, Alimoghaddam K, Bahosh G, Behfar M, Ghavamzadeh A (2013) The treatment of children suffering from chronic myelogenous leukemia: a comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 17(4):380–386

    Article  PubMed  Google Scholar 

  55. Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL (2012) Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leuk Lymphoma 53(7):1321–1326

    Article  CAS  PubMed  Google Scholar 

  56. Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ (2011) Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117(11):3032–3040

    Article  CAS  PubMed  Google Scholar 

  57. Hehlmann R (2012) How I treat CML blast crisis. Blood 120(4):737–747

    Article  CAS  PubMed  Google Scholar 

  58. O’Hare T, Zabriskie MS, Eiring AM, Deininger MW (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12(8):513–526. doi:10.1038/nrc3317

    Article  PubMed  Google Scholar 

  59. Pavlů J, Apperley JF (2013) Allogeneic stem cell transplantation for chronic myeloid leukemia. Curr Hematol Malig Rep 8(1):43–51. doi:10.1007/s11899-012-0149-7

    Article  PubMed  Google Scholar 

  60. Benyamini N, Rowe JM (2013) Is there a role for allogeneic transplantation in chronic myeloid leukemia? Expert Rev Hematol 6(6):759–765

    Article  CAS  PubMed  Google Scholar 

  61. Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981–1987

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Gratwohl A, Brand R, Niederwieser D et al (2011) Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29:1980–1986

    Article  PubMed  Google Scholar 

  63. Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CML, Group S (2014) The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 123(16):2494–2496. doi:10.1182/blood-2013-11-539742

    Article  CAS  PubMed  Google Scholar 

  64. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon F-X, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884. doi:10.1182/blood-2013-05-501569

    Article  CAS  PubMed  Google Scholar 

  65. Mo XD, Jiang Q, Xu LP, Liu DH, Liu KY, Jiang B, Jiang H, Chen H, Chen YH, Zhang XH, Han W, Wang Y, Huang XJ (2014) Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 49(4):576–580. doi:10.1038/bmt.2013.232

    Article  CAS  PubMed  Google Scholar 

  66. Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R (2012) Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess 16(42):1–277. doi:10.3310/hta16420

    Article  Google Scholar 

  67. Experts in Chronic Myeloid Leukemia (2013) The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121(22):4439–4442. doi:10.1182/blood-2013-03-490003

    Article  PubMed Central  Google Scholar 

  68. Yeung KY, Gooley TA, Zhang A, Raftery AE, Radich JP, Oehler VG (2012) Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data. Bioinformatics 28(6):823–830

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Cornelissen JJ, Gratwohl A, Schlenk RF et al (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 9:579–590

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The manuscript is solely written by the authors. A.G. declares no conflicts of interest; H.B. declares no conflicts of interest; J.P. declares no conflicts of interest.

Author information

Authors and Affiliations

  1. Hematology, University Hospital, Dittingerstrasse 4, 4053, Basel, Switzerland

    Alois Gratwohl, Helen Baldomero & Jakob Passweg

Authors
  1. Alois Gratwohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen Baldomero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jakob Passweg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alois Gratwohl.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gratwohl, A., Baldomero, H. & Passweg, J. The role of hematopoietic stem cell transplantation in chronic myeloid leukemia. Ann Hematol 94 (Suppl 2), 177–186 (2015). https://doi.org/10.1007/s00277-015-2313-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2313-3

Keywords

Search

Navigation